Veterinary Oncology Market Report 2026

The veterinary oncology market size has grown rapidly in recent years. It will grow from $0.45 billion in 2025 to $0.5 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to rising incidence of cancer in companion animals, growing awareness of veterinary oncology services, technological advancements in surgical and radiology equipment, expansion of veterinary hospitals and specialty clinics, adoption of conventional chemotherapy treatments.

The veterinary oncology market size is expected to see rapid growth in the next few years. It will grow to $0.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for personalized and targeted therapies, growth in advanced radiology and imaging adoption, rising use of immunotherapy and supportive care, development of minimally invasive surgical techniques, integration of combination chemotherapy and targeted therapy protocols. Major trends in the forecast period include expansion of targeted and personalized veterinary cancer therapies, growth in minimally invasive surgical techniques, increasing adoption of advanced radiology and imaging technologies, development of combination chemotherapy protocols, integration of immunotherapy and supportive care in treatment plans.

The rising prevalence of cancer in pets is anticipated to significantly drive the growth of the veterinary oncology market in the future. Cancer is a condition characterized by uncontrolled cell growth that can spread to other parts of the body, and in pets, it often presents as physical symptoms like tumors or swelling. Veterinary oncology focuses on diagnosing and treating cancer in animals, aiming to reduce metastasis and the spread of the disease. Consequently, an increase in pet cancer cases is expected to elevate the demand for veterinary oncology services. For instance, according to the Cancer Letter, a US-based publication dedicated to cancer research, an estimated 6 million pet dogs will be diagnosed with cancer in the United States in 2024. Additionally, data from the British Small Animal Veterinary Association (BSAVA), a UK-based veterinary organization, indicated in November 2023 that approximately 1 in 4 dogs and 1 in 5 cats will be diagnosed with cancer during their lifetime. Thus, the increasing prevalence of cancer in pets is driving the veterinary oncology market forward.

Leading companies in the veterinary oncology market are concentrating on developing neoantigens, which are unique tumor-specific antigens resulting from mutations in cancer cells. Neoantigens are distinct protein fragments produced by tumor-specific mutations, differentiating them from normal antigens found in healthy tissues. These proteins arise from genetic alterations (mutations) in the tumor's DNA. For example, in October 2024, a US-based biotechnology company launched a cancer vaccine trial for dogs. The exploration of neoantigens is central to the development of cancer vaccines and other forms of immunotherapy, aiming to enhance the immune response specifically against cancer cells while minimizing the impact on normal cells.

In September 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. Through this acquisition, Boehringer Ingelheim aimed to strengthen its veterinary therapeutics pipeline by integrating Saiba’s innovative technology platform for developing novel therapeutic medicines, including potential treatments for chronic diseases such as cancer in pets. Saiba Animal Health AG is a Switzerland-based developer of therapeutic vaccines and advanced technology platforms targeting chronic conditions in companion animals, with potential applications across oncology and related therapeutic areas.

Major companies operating in the veterinary oncology market are PetCure Oncology Inc., Zoetis Inc., Varian Medical Systems Inc., Accuray Incorporated, Boehringer Ingelheim International GmbH, Elanco Animal Health Inc., One Health Company Inc., Regeneus Limited, VetDC Inc., Pharmaust Limited, AdvaVet Inc., Nippon Zenyaku Kogyo Company Limited, AB Science SAS, Pfizer Inc., Jaguar Animal Health Solutions Inc., Orion Corporation A/B, Virbac SA, SeQuent Scientific Limited, Ceva Santé Animale S.A., Vetoquinol S.A., IDVet Inc., Bayer Aktiengesellschaft, ZENOAQ GmbH, Oncovet Clinical Research Inc.

Asia-Pacific was the largest region in the veterinary oncology market in 2025. North America is expected to be the fastest-growing region in the veterinary oncology market report during the forecast period. The regions covered in the veterinary oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the veterinary oncology market by raising the cost of imported surgical instruments, radiology devices, chemotherapy drugs, and immunotherapy agents, affecting pricing and accessibility in veterinary hospitals and clinics. Segments such as surgery, radiology, and chemotherapy are most impacted, particularly in regions like North America and Europe reliant on imported oncology products. However, tariffs have also encouraged domestic manufacturing, promoted cost-effective alternatives, and stimulated innovation in local oncology solutions, benefiting regional players.

The veterinary oncology market research report is one of a series of new reports that provides veterinary oncology market statistics, including veterinary oncology industry global market size, regional shares, competitors with a veterinary oncology market share, detailed veterinary oncology market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary oncology industry. This veterinary oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary oncology involves the specialized diagnosis and treatment of cancer in animals, aiming to integrate cancer therapies while maintaining the overall quality of life for the affected animals. This field focuses on providing cancer medicine and treatment services tailored to the unique needs of animals.

The primary types of therapies in veterinary oncology include surgery, radiology, chemotherapy, and other specialized treatments. Surgery involves procedures to either remove or repair affected body parts or to assess the presence of disease. A diverse range of animals, including equines, canines, felines, and other species, are involved in veterinary oncology. The field encompasses various cancer types such as lymphomas, mast cell cancer, mammary cancer, squamous cell cancer, among others, specific to different animal species.

The veterinary oncology market includes revenues earned by entities by providing cryosurgery, comprehensive care, immunotherapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.